The Antiinflammatory Activity of the Immunomodulator Wy-18,251 (3-(p-chlorophenyl)thiazolo[3,2-a]benzimidazole-2-acetic Acid)

Overview

Journal Agents Actions

Specialty Pharmacology

Date 1985 Oct 1

PMID 3936345

Citations 5

Authors

S C Gilman

R P Carlson

J Chang

A J Lewis

Affiliations

Soon will be listed here.

Abstract

The antiinflammatory activity of the immunomodulatory agent Wy-18,251 (3-(p-chlorophenyl)thiazolo-[3,2-a]benzimidazole-2-acetic acid) was examined using a variety of antiinflammatory, analgesic and antipyretic animal models in comparison to aspirin, levamisole and indomethacin. The acute antiinflammatory and analgesic activity of Wy-18,251 (ED50 = 100-200 mg/kg, p.o.) was similar to aspirin, but in contrast to aspirin Wy-18,251 failed to demonstrate antipyretic activity. Wy-18,251 (10-100 mg/kg, p.o.) also inhibited chronic inflammatory responses in the adjuvant- and collagen-induced arthritis models. Wy-18,251 was a modest inhibitor of prostaglandin biosynthesis but did not inhibit either 5- or 15-lipoxygenase enzymes. Wy-18,251 (up to 480 mg/kg, p.o.) produced little gastrointestinal pathology in 16 h fasted rats. The combined immunomodulatory and antiinflammatory activity of Wy-18,251 suggests that this agent may have therapeutic promise in certain immunoinflammatory diseases including rheumatoid arthritis.

Citing Articles

In Vivo Anti-Inflammatory Effect, Antioxidant Activity, and Polyphenolic Content of Extracts from By-Products.

Chel-Guerrero L, Castaneda-Corral G, Lopez-Castillo M, Scampicchio M, Morozova K, Oney-Montalvo J Molecules. 2022; 27(4).

PMID: 35209112 PMC: 8880488. DOI: 10.3390/molecules27041323.

Synthesis and Antiproliferative Activities of Benzimidazole-Based Sulfide and Sulfoxide Derivatives.

Gaballah S, El-Nezhawy A, Amer H, Ali M, Mahmoud A, Hofinger-Horvath A Sci Pharm. 2016; 84(1):1-18.

PMID: 27110495 PMC: 4839274. DOI: 10.3797/scipharm.1507-02.

Effects of tilomisole, indomethacin and levamisole on regulation of Epstein Barr virus-induced B cell proliferation by peripheral blood mononuclear cells from normal individuals and patients with rheumatoid arthritis.

Gilman S, Bluestein H Agents Actions. 1987; 21(3-4):266-8.

PMID: 2825478 DOI: 10.1007/BF01966486.

Interference of levamisole with cerebral edema.

Casaco A, Carvajal D Agents Actions. 1990; 31(1-2):113-6.

PMID: 2285016 DOI: 10.1007/BF02003230.

Interaction studies of tilomisole, aspirin, and naproxen in acute and chronic inflammation with assessment of gastrointestinal irritancy in the rat.

Calhoun W, Gilman S, Datko L, Copenhaver T, Carlson R Agents Actions. 1992; 36(1-2):99-106.

PMID: 1414694 DOI: 10.1007/BF01991236.

References

Flower R . Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974; 26(1):33-67. View

COLOT M, Micksche M . Influence of thia-benzimidazole Wy 18251 of cancer patients' lymphocyte reactivity. J Immunopharmacol. 1982; 4(4):367-76. DOI: 10.3109/08923978209019454. View

Fenichel R, Dheer S, Grant N, Scott D, Bloom R, GREGORY F . Immunomodulating activity of 3-(p-chlorophenyl)thiazolo-[3,2-a] benzimidazole-2-acetic acid (Wy-18,251, NSC 310633) in mice implanted with Lewis lung tumor. Effect of Wy-18,251 on lymphocyte proliferation and phagocytosis. J Immunopharmacol. 1983; 5(4):333-40. DOI: 10.3109/08923978309026452. View

Zvaifler N . The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol. 1973; 16(0):265-336. DOI: 10.1016/s0065-2776(08)60299-0. View

Flower R, Cheung H, Cushman D . Quantitative determination of prostaglandins and malondialdehyde formed by the arachidonate oxygenase (prostaglandin synthetase) system of bovine seminal vesicle. Prostaglandins. 1973; 4(3):325-41. DOI: 10.1016/0090-6980(73)90020-8. View

Gibson T, Huskisson E, Wojtulewski J, Scott P, Balme H, Burry H . Evidence that D-penicillamine alters the course of rheumatoid arthritis. Rheumatol Rehabil. 1976; 15(3):211-5. DOI: 10.1093/rheumatology/15.3.211. View

Fenichel R, Alburn H, Schreck P, Bloom R, GREGORY F . Immunomodulating and antimetastatic activity of 3-(p-chlorophenyl) thiazolo[3,2-a]benzimidazole-2-acetic acid (Wy-18,251, NSC 310633). J Immunopharmacol. 1980; 2(4):491-508. DOI: 10.3109/08923978009026408. View

Chang J, Wigley F, Newcombe D . Neutral protease activation of peritoneal macrophage prostaglandin synthesis. Proc Natl Acad Sci U S A. 1980; 77(8):4736-40. PMC: 349921. DOI: 10.1073/pnas.77.8.4736. View

Stuart J, Cremer M, Dixit S, Kang A, Townes A . Collagen-induced arthritis in rats. Comparison of vitreous and cartilage-derived collagens. Arthritis Rheum. 1979; 22(4):347-52. DOI: 10.1002/art.1780220406. View

10.

RANDALL L, SELITTO J . A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther. 1957; 111(4):409-19. View

11.

Lewis A, Parker J, DiLuigi J, Datko L, Carlson R . Immunomodulation of delayed hypersensitivity to methylated bovine serum albumin (MBSA) in mice using subliminal and normal sensitization procedures. J Immunopharmacol. 1981; 3(3-4):289-307. DOI: 10.3109/08923978109031063. View

12.

Lipsky P . Remission-inducing therapy in rheumatoid arthritis. Am J Med. 1983; 75(4B):40-9. DOI: 10.1016/0002-9343(83)90327-3. View

13.

Luukkainen R, Kajander A, Isomaki H . Effect of gold on progression of erosions in rheumatoid arthritis. Better results with early treatment. Scand J Rheumatol. 1977; 6(3):189-92. DOI: 10.3109/03009747709095448. View

14.

Flower R, Vane J . Inhibition of prostaglandin biosynthesis. Biochem Pharmacol. 1974; 23(10):1439-50. DOI: 10.1016/0006-2952(74)90381-5. View

15.

Atkinson D . Nonsteroidal acidic anti-inflammatory agents: do they constitute a single drug class?. Agents Actions. 1979; 9(5-6):480-2. DOI: 10.1007/BF01968115. View

16.

Hellon R, Townsend Y . Mechanisms of fever. Pharmacol Ther. 1982; 19(2):211-44. DOI: 10.1016/0163-7258(82)90063-8. View

17.

Chang J, Skowronek M, Cherney M, Lewis A . Differential effects of putative lipoxygenase inhibitors on arachidonic acid metabolism in cell-free and intact cell preparations. Inflammation. 1984; 8(2):143-55. DOI: 10.1007/BF00916090. View

18.

Hunneyball I . Recent developments in disease-modifying antirheumatic drugs. Prog Drug Res. 1980; 24:101-216. DOI: 10.1007/978-3-0348-7108-2_4. View